STOCK Vav2^tm1Kdf Vav1^tm2Bbd/Cnbc

Status	Available to order
EMMA ID	EM:08030
International strain name	STOCK Vav2^tm1Kdf Vav1^tm2Bbd/Cnbc
Alternative name	Double KO: vav1_KO; vav2_KO or Vav1tm2Bbd; Vav2tm1Kdf
Strain type	Targeted Mutant Strains : Knock-out
Allele/Transgene symbol	Vav2^tm1Kdf,
Gene/Transgene symbol	Vav2

Information from provider

Provider	Mariano Barbacid
Provider affiliation	Molecular Oncology, Centro Nacional de Investigaciones Oncologicas
Genetic information	In the Vav1 allele sequences encoding amino acids 135-195 comprising the entire acidic domain were replaced with a PGK-neo cassette via homologous recombination. Gene expression was absent in thymocytes of homozygous mutant animals. In the Vav2 allele a lacZ-neo cassette was fused in-frame to amino acids 150-155 of exon 5 and introduced via homologous recombination. Western blot analysis of spleen tissue from homozygous mutant animals confirmed the absence of gene expression.
Phenotypic information	Homozygous: Combined deletion of both Vav1 and Vav2 in mice results in a marked reduction in mature B lymphocyte numbers. Vav1(-/-),Vav-2(-/-) B cells are unresponsive to B cell antigen receptor (BCR)-driven proliferation in vitro and to thymus-independent antigen in vivo. BCR-stimulated intracellular calcium mobilization is greatly impaired in Vav1(-/-),Vav-2(-/-) B cells. Heterozygous: Heterozygous mice are viable
Breeding history	Chimeras were crossed with CD1 females for germ-line transmission analysis. Heterozygous animals for each allele were crossed among themselves to generate corresponding homozygous animals. To obtain the double mutant strain homozygous animals for each allele were crossbred. Currently maintained as mixed CD1 and 129.
References	Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor.;Fischer K D, Kong Y Y, Nishina H, Tedford K, Marengère L E, Kozieradzki I, Sasaki T, Starr M, Chan G, Gardener S, Nghiem M P, Bouchard D, Barbacid M, Bernstein A, Penninger J M, ;1998;Current biology : CB;8;554-62; 9601639 Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling.;Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, Barbacid M, Fischer K D, ;2001;Nature immunology;2;548-55; 11376343
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	no
Immunocompromised	no

Information from EMMA

Archiving centre	CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archiving	homozygous CD-1 outbred stock (syn.: outbr. CD-1 or CD1, Swiss CD-1 or CD1, ICR(CD-1), etc.), homozygous CD-1 outbred stock (syn.: outbr. CD-1 or CD1, Swiss CD-1 or CD1, ICR(CD-1), etc.)
Stage of embryos	4/8-cell

Disease and phenotype information

MGI phenotypes (allele matching)

abnormal T cell physiology / MGI
abnormal positive T cell selection / MGI
decreased T cell number / MGI
impaired natural killer cell mediated cytotoxicity / MGI
decreased double-positive T cell number / MGI
immune system phenotype / MGI
decreased NK T cell number / MGI
abnormal CD4-positive T cell differentiation / MGI
decreased interleukin-4 secretion / MGI
decreased IgG level / MGI
abnormal T cell differentiation / MGI
abnormal B cell number / MGI
decreased B-1 B cell number / MGI
abnormal response to infection / MGI
increased double-negative T cell number / MGI
decreased B cell proliferation / MGI
abnormal T cell number / MGI
decreased CD4-positive, alpha beta T cell number / MGI
decreased CD8-positive, alpha-beta T cell number / MGI
increased transitional stage B cell number / MGI
decreased IgG1 level / MGI
decreased IgG2a level / MGI
decreased IgG3 level / MGI
abnormal splenic cell ratio / MGI
abnormal lymph node cell ratio / MGI
thymus hypoplasia / MGI
abnormal T cell activation / MGI
decreased T cell proliferation / MGI
decreased interleukin-2 secretion / MGI
abnormal iridocorneal angle / MGI
ocular hypertension / MGI
anterior iris synechia / MGI
decreased mature B cell number / MGI

Literature references

Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor.;Fischer K D, Kong Y Y, Nishina H, Tedford K, Marengère L E, Kozieradzki I, Sasaki T, Starr M, Chan G, Gardener S, Nghiem M P, Bouchard D, Barbacid M, Bernstein A, Penninger J M, ;1998;Current biology : CB;8;554-62; 9601639
Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling.;Tedford K, Nitschke L, Girkontaite I, Charlesworth A, Chan G, Sakk V, Barbacid M, Fischer K D, ;2001;Nature immunology;2;548-55; 11376343

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.

STOCK Vav2tm1Kdf Vav1tm2Bbd/Cnbc